Altimmune, Inc.
Clinical trials sponsored by Altimmune, Inc., explained in plain language.
-
New drug shows promise in cutting heavy drinking days
Disease control CompletedThis study tests a weekly injection called pemvidutide to see if it can reduce heavy drinking in adults with alcohol use disorder who are also overweight or obese. About 100 participants will receive either the drug or a placebo for 24 weeks. The main goal is to measure the chang…
Phase: PHASE2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New shot shows promise against fatty liver disease
Disease control CompletedThis study tested a weekly injection called pemvidutide in 212 adults with NASH, a serious liver condition linked to fat buildup. The goal was to see if the drug could reduce liver fat and scarring without worsening the disease. Participants received either the drug or a placebo …
Phase: PHASE2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC